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Abstract: GSK256066 is a selective phosphodiesterase 4 inhibitor that can be given by inhalation, minimising the
potential for side effects. We evaluated the effects of GSK256066 on airway responses to allergen challenge in mild
asthmatics.
Methods: In a randomised, double blind, cross-over study, 24 steroid naive atopic asthmatics with both early (EAR)
and late (LAR) responses to inhaled allergen received inhaled GSK256066 87.5 mcg once per day and placebo for 7
days, followed by allergen challenge. Methacholine reactivity was measured 24 h post-allergen. Plasma
pharmacokinetics were measured. The primary endpoint was the effect on LAR.
Results: GSK256066 significantly reduced the LAR, attenuating the fall in minimum and weighted mean FEV1 by
26.2% (p = 0.007) and 34.3% (p = 0.005) respectively compared to placebo. GSK256066 significantly reduced the
EAR, inhibiting the fall in minimum and weighted mean FEV1 by 40.9% (p = 0.014) and 57.2% (p = 0.014)
respectively compared to placebo. There was no effect on pre-allergen FEV1 or methacholine reactivity post
allergen. GSK256066 was well tolerated, with low systemic exposure; plasma levels were not measurable after 4
hours in the majority of subjects.
Conclusions: GSK256066 demonstrated a protective effect on the EAR and LAR. This is the first inhaled PDE4
inhibitor to show therapeutic potential in asthma.
Trial Registration: This study is registered on clinicaltrials.gov NCT00380354
Introduction
Inhaled corticosteroids are the cornerstone of anti-
inflammatory treatment in asthma [1]. However, many
patients remain symptomatic despite high doses of
inhaled corticosteroids, even when combined with long
acting beta agonists [2,3]. New asthma treatments tar-
geting inflammation are needed.
Adenosine monophosphate (cAMP) and cyclic guano-
sine monophosphate (cGMP) cause smooth muscle
relaxation and regulate immune cell function [4]. These
intracellular signalling molecules are inactivated by the
phosphodiesterase (PDE) family of metallophosphohy-
drolases, which can lead to smooth muscle contraction
and increased immune cell activation [4,5]. Therefore,
the non-selective oral PDE inhibitor theophylline has
been used as a treatment for asthma for many years.
However, it has a low therapeutic index due to limited
potency and a poor side effect profile [6,7]. The PDE4
subfamily are highly expressed on inflammatory cells
such as eosinophils, lymphocytes, macrophages and neu-
trophils [5,8], so selective PDE4 inhibitors have recently
been developed with the aim of improving the therapeu-
tic index. Animal models have shown this approach to
be highly effective in reducing allergen induced inflam-
mation [9,10]. Clinical studies have shown efficacy for
orally administered PDE4 selective inhibitors on relevant
asthma endpoints such as inhibition of allergen chal-
lenge [11,12] and exercise induced bronchoconstriction
[13], as well as improvements in lung function [14].
However, the tolerability of these orally administered
drugs is still limited by side effects such as gastro-intest-
inal symptoms [15-17].
The delivery of a selective and potent PDE4 inhibitor
by inhalation may improve the therapeutic index by
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directly to the target organ to increase therapeutic
effects. GSK256066 (6-({3- [(dimethylamino) carbonyl]
phenyl}sulfonyl)-8-methyl-4-{ [3-methyloxy)phenyl]
amino}-3-quinolinecarboxamide) is a PDE4 inhibitor
that can be delivered by inhalation. This compound is a
very high affinity, slow- and tight-binding inhibitor of
PDE4 that is highly selective for PDE4 over other PDEs
such as 1, 2, 3, 5, 6 and 7, and shows efficacy in animal
models of pulmonary inflammation [18].
The aim of this study was to investigate the effects of
selective inhibition of PDE4 with GSK256066 delivered
by inhalation in the experimental allergen challenge
model of allergic asthma. Wep e r f o r m e dad o u b l eb l i n d ,
placebo controlled, crossover study in steroid naïve
asthma patients to assess the effectiveness of GSK256066.
We also measured systemic exposure to GSK256066.
Methods
Subjects
24 steroid naïve patients with physician diagnosed
asthma for at least 6 months were recruited - the demo-
graphy of the patients is shown in table 1. Subjects were
required to be aged 18 to 55 years and non-smokers for
at least 6 months with less than a 10 pack year history.
At screening patients were required to have a forced
expiratory volume in 1 second (FEV1) > 75% predicted,
have a positive skin test to either house dust mite, grass
pollen or cat allergen, and to demonstrate both an early
and late asthmatic reaction to one of these allergens
when inhaled. Subjects we also required to have haema-
tology, biochemistry and creatinine clearance values
within the normal ranges. All patients provided written
informed consent. The study was approved by the local
research ethics committee.
Study Design
This was a two centre, double-blind, randomised, pla-
cebo controlled, cross-over study. Eligible subjects were
randomised to receive GSK256066 87.5 μg or matching
placebo using an Accuhaler™ once daily for 7 days - see
Fig 1. The washout period was 14 - 21 days between
treatment periods. Dosing was performed under supervi-
sion at the sites on Day 1 and Day 7. On days 2-6
subjects were instructed to take the study medication at
the same time of day, and were required to complete a
diary card to document the time that medication was
taken. Heart rate, blood pressure, ECGs, FEV1 and
exhaled nitric oxide (FeNO) were measured pre-dose on
days 1 and 7, and at 1 hr post-dose. On day 7, an
inhaled allergen challenge was subsequently performed
after the 1 hour post-dose FEV1 and FeNO measure-
ments. Methacholine challenge was then performed at
24 hours post allergen challenge. Adverse events and
beta agonist use were monitored throughout the study
with the aid of diary cards.
Allergen and Methacholine Challenges
Bronchial challenges were performed as we have pre-
viously described [19] using a Mefar Dosimeter (Mefar-
Bologna). Allergen for skin prick tests (Soluprick SQ,
Alk Abelló (UK) Ltd) was stored at 4°C; each subject
was assessed for sensitivity to house dust mite, cat, grass
pollen, and positive and negative controls. The allergen
for inhalation was selected according to the largest skin
test wheal (positive >3 mm) and clinical history. Fresh
solutions of allergen were made up in 0.9% saline in
doubling concentrations from 250 SQ-U/ml to 32 000
SQ-U/ml. At screening, incremental doses of allergen
were inhaled [19] until an early asthmatic response
(EAR) was observed, defined as a fall in FEV1 of ≥ 20%
from the post saline value, on at least one occasion,
between 5 and 30 minutes after the final concentration
of allergen. The late asthmatic response (LAR) was
defined as a fall in FEV1 of ≥ 15% from the post saline
value, on at least three occasions, two of which must be
consecutive, between 4 and 10 hours after the final con-
centration of allergen. During the treatment periods, the
total dose of allergen required to cause an EAR and
LAR was administered as a single bolus dose.
Subjects were administered doubling concentrations of
methacholine from 0.03125 to 32 mg/ml until a ≥ 20%
fall in FEV1 was achieved or the highest concentration
of methacholine was administered. The provocative con-
centration required to reduce the FEV1 by 20% of the
post-saline baseline value (PC20) was derived by linear
interpolation between the lowest concentration that
caused a >20% fall and the preceding concentration. If
the FEV1 did not fall by more than 20% following the
highest concentration then the PC20 was set to the
highest concentration given in the challenge. If the FEV1
fell by more than 20% following the first concentration
the PC20 was derived as [20× lowest concentration]/[%
fall following lowest concentration].
FeNO
FeNO was measured using the Ecomedics AG analyser
CLD 88 at a flow of 50 ml/s. Three acceptable readings
Table 1 Subject Demography
Variable Value
Age/years 31 (20 - 46)
Gender (Male/Female) 13/11
FEV1 % predicted 90.1 (71.3 - 111.8)
Allergen used for bronchial
challenge
14 dust mite, 5 cat dander,
5 grass mix
Mean (range) shown for age and FEV1.
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for analysis.
Pharmacokinetic Sampling and Bioanalytical Method
On days 1 and 7, blood samples were collected at pre-
d o s e ,1 0m i n ,3 0m i n ,4 5m i na n d1 ,2 ,3 ,4 ,6 ,8 ,1 0 ,1 1 ,
12 and 24 hrs post dose for measurement of the levels of
GSK256066 in plasma. The active metabolite
GSK614917, which is 1.7 fold less potent than the parent
compound, was also measured. These pharmacokinetic
analyses were performed by protein precipitation, fol-
lowed by HPLC/MS/MS. The lower limit of quantifica-
tion (LLOQ) for GSK256066 and GSK614917 was 5 pg/
mL, with an upper limit of quantification of 2000 pg/mL
Statistics
Minimum LAR was derived as the minimum FEV1 value
over 4-10 hrs post allergen challenge. Minimum EAR
was derived as the minimum FEV1 over 0-2 hrs post
allergen challenge. Weighted mean LAR and EAR end-
points were derived by calculating the AUC over the
relevant time interval using the linear trapezoidal rule
and dividing by the time interval. The sample size was
based on a power calculation using our previous
allergen challenge data [19]; in order to detect a 50%
attenuation of the minimum LAR, with 90% power at
the two-sided 5% significance level, 23 evaluable were
required. Statistical analysis was performed on each of
the absolute change from baseline LAR and EAR end-
points to compare GSK256066 with placebo. A mixed
effects model was fitted with the factors treatment, per-
iod and Day 7 post-saline FEV1 as fixed effects and sub-
ject as a random effect. Absolute change from post-
saline FEV1 data over planned relative time were
obtained from a repeated measures statistical analysis,
adjusting for the terms of period, treatment group, per-
iod-level post-saline baseline, subject-level post-saline
baseline, planned relative time, treatment group by
planned relative time interaction and period-level post-
saline baseline by planned relative time interaction as
fixed effects and subject as a random effect. Day 7 FEV1
data (pre-dose and 1 h post-dose) were also analysed
using a mixed effects model, adjusting for the fixed
effects treatment, period and Day 1 pre-dose FEV1 and
the random effect subject. Statistical analysis was per-
formed on the log2-transformed values of the provoca-
tive concentration of methacholine required to produce
a2 0 %r e d u c t i o ni nF E V 1( P C 2 0 )t oc o m p a r e
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Figure 1 Flow chart showing study design. FeNO denotes exhaled nitric oxide. Allergen = inhaled allergen challenge. Methacholine = inhaled
methacholine challenge.
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fitted with the factors treatment and period treated as
fixed effects and subject as a random effect. FeNO
change from baseline ratio at all time points were ana-
lysed following a loge-transformation to compare
GSK256066 with placebo. A mixed effects model was
fitted with the fixed effects period, treatment group,
subject-level loge-transformed baseline, period-level loge-
transformed baseline, planned relative time, treatment
group by planned relative time interaction term and per-
iod-level loge-transformed baseline by planned relative
time interaction term and the random effect subject.
Values for the following pharmacokinetic were esti-
mated directly from raw plasma concentration data:
maximum plasma concentration (Cmax), time of maxi-
mum observed concentration (Tmax), and time of the
last observable concentration (Tlast). Area under the
plasma concentration-time curve from time zero to
Tlast (AUC (0-t)) was estimated for subjects with at
least 3 consecutive observable concentration values with
the log up/linear down trapezoidal method using Win-
nonlin professional version 5.2 (Pharsight Corporation,
Cary, NC, USA).
Results
Of the 24 subjects randomised, 19 completed the study
(see Fig 2). One subject developed cough and wheeze
after inhalation of 3 doses of GSK256066 which resolved
within 24 hrs. Two subjects had evidence of high creati-
nine clearance during the study; one after placebo, and
one after three doses of GSK256066. Two withdrawals
occurred during placebo treatment (the subjects did not
receive GSK256066); one subject tested positive for
cocaine, and one subject had abnormal ECG changes.
Allergen Challenge
GSK256066 significantly reduced the EAR (see Fig 3),
inhibiting the fall in both minimum and weighted mean
FEV1 by 40.9% (p = 0.014) and 57.2% (p = 0.014) respec-
tively compared to placebo. GSK256066 also significantly
reduced the LAR, attenuating the fall in both minimum
and weighted mean FEV1 by 26.2% (p = 0.007) and 34.3%
(p = 0.005) respectively compared to placebo.
Methacholine reactivity at 24 hrs post allergen chal-
lenge was not different after treatment with GSK256066
compared to placebo; the PC20 was 0.31 compared to
0.39 mg/mL respectively, geometric mean (95% CI) dou-
bling dose difference -0.31 (-1.18 to 0.57).
Pulmonary Function and FeNO
The FEV1 and FeNO measurements on day 7 at pre-
dose and 1 hr post dose are shown in tables 2 and 3
respectively. There was no difference between the treat-
ments for either of these measurements.
Figure 2 Flow chart showing withdrawal of subjects during the study.
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The pharmacokinetic parameters for GSK256066 are
shown in table 4, with individual data shown in Fig 4.
GSK256066 concentrations were above the LLOQ in 18
o u to f2 2s u b j e c t so nD a y1a n d1 7o u to f1 9s u b j e c t s
on Day 7. Despite a very sensitive bioanalytical method
(LLOQ 5 pg/mL), on day 1, the drug levels were below
the LLOQ after 4 hrs post dose for the majority (18) of
the 22 subjects. On day 7, 10 of the 19 subjects had
drug levels were below the LLOQ after 4 hrs post dose.
Only 1 subject on day 7 had levels above the LLOQ
after 12 hrs. The systemic exposure to GSK614917 was
also low, as only 8 out of 22 subjects had levels above
the LLOQ on day 1, and 9 out of 19 on day 7. Variabil-
ity in systemic exposure was high (coefficients of
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Figure 3 Early and late asthmatic response to inhaled allergen challenge after 7 days treatment with either GSK256066 or placebo.
Means and 95% confidence intervals of change in FEV1 compared to post saline value shown.
Table 2 Lung Function
Day 1
Pre-dose
Day 7
Pre-dose
Day 7
1 hr post-dose
GSK256066 (L) 3.29
(2.88 to 3.69)
3.36
(2.94 to 3.79)
3.47
(3.04 to 3.90)
Placebo (L) 3.27
(2.85 to 3.69)
3.26
(2.91 to 3.60)
3.36
(2.99 to 3.73)
Adjusted treatment
difference GSK256066
vs placebo (L)
0.09
(-0.03 to 0.20)
0.09
(-0.08 to 0.27)
Mean values shown, and with adjusted mean (95% confidence intervals) for
treatment differences and ratios
Table 3 Exhaled Nitric Oxide
Day 1
Pre-dose
Day 7
Pre-dose
Day 7
1 hr post-dose
GSK256066 (ppb) 39.9
(31.0 to 51.3)
34.7
(26.7 to 45.0)
36.1
(28.1 to 46.3)
Placebo (ppb) 34.5
(24.6 to 48.4)
33.1
(22.8 to 47.9)
34.3
(23.2 to 50.6)
Adjusted treatment
ratio GSK256066 vs
placebo
0.98
(0.85 to 1.31)
1.03
(0.88 to 1.20)
Mean values shown, and with adjusted mean (95% confidence intervals) for
treatment differences and ratios
Table 4 Pharmacokinetic Analysis for GSK256066
Parameter unit Day 1 Day 7
AUC (0-t) pg.h./mL 36.8 (93) 64.8 (89)
Cmax Pg/mL 18.3 (68) 17.3 (63)
Tmax h 1.0 (0.17-3.00) 1.0 (0.17-11.0)
Tlast h 3.0 (0.5-6.0) 4.0 (1.0-24)
Values are geometric means (CV%) for AUC(0-t) and Cmax, and medians
(range) for Tmax and Tlast. 0-t = From 0 hrs to time of last measurable
concentration. N = 18 on Day 1, and n = 17 on Day 7.
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68%, respectively), reflecting the difficulty in accurate
characterisation of pharmacokinetic parameters when
measurable concentrations are close to the limit of
detection (Tlast ranged from 0.5-24 hours in this study).
Discussion
To our knowledge, this is the first study to show that an
inhaled PDE4 inhibitor inhibits the response to allergen
challenge in asthma. This placebo controlled study
demonstrated that GSK256066 administered for 7 days
significantly attenuated the fall in lung function in
patients with asthma caused by inhaled allergen
challenge. GSK256066 had no effect on the secondary
endpoints of methacholine reactivity post allergen chal-
lenge or exhaled nitric oxide. Nevertheless, the effects of
GSK256066 on the allergen response which was the pri-
mary endpoint indicate that this drug has therapeutic
potential for the treatment of asthma. The delivery of
this PDE4 inhibitor by inhalation was associated with
low systemic exposure. Larger clinical trials are needed
to study the therapeutic index in more detail.
Inhaled allergen challenge is a well recognised and
robust model that is commonly used to assess the thera-
peutic potential of novel treatments for asthma
[11,12,19-24]. Comparing the results of different allergen
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Figure 4 Plot of individual derived plasma PK parameters AUC(0-t) and Cmax for GSK256066 on days 1 and 7. Summary Box and
Whisker plot overlaid. Open squares represent individual values. Central line, box and whisker limits represent median, interquartile range and
most extreme value with 1.5× interquartile range, respectively.
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odological details such as the period of measurement of
the late response can vary between studies (we mea-
sured up to 10 hrs while some studies only measure up
to 7 hrs), and individual patient characteristics may dif-
f e r .T h er e s u l t so ft h ec u r r e n ts t u d ya r et h e r e f o r en o t
directly comparable to the previous publication invol-
ving the orally administered PDE4 inhibitor roflumilast,
which inhibited the maximal fall in the EAR and LAR
by 14% and 33% respectively. Inhibition of 40.9% and
26.2% respectively were observed in the current study.
Direct head-to-head comparisons would be the best way
to compare GSK256066 to roflumilast.
Inhaled corticosteroids attenuate the fall in lung func-
tion caused by inhaled allergen, with results varying
between studies for the absolute magnitude of inhibition
depending on the dose and type of corticosteroid used
[20,22-24]. However, inhaled corticosteroids generally
have a minimal effect on the EAR [20,22,23]. This may
be due to the inability of corticosteroids to prevent mast
cell degranulation. In contrast, GSK256066 had a very
significant inhibitory effect on the EAR. PDE4 inhibition
by GSK256066 may therefore offer more protection
than corticosteroids against acute bronchoconstriction
in clinical practice.
The LAR is characterised by an inflammatory cell
influx into the airways, comprising a variety of cell types
including eosinophils, basophils and lymphocytes that
are recruited by T-helper 2 (TH2) cytokines [25]. The
LAR is therefore a well validated model to study inhibi-
tion of TH2 driven inflammatory cell influx into the air-
ways. Corticosteroids inhibit inflammatory gene
transcription [26], and therefore decrease the number
and activity of inflammatory cells at tissue sites of
inflammation. Inhaled corticosteroids therefore inhibit
airway inflammation during the LAR [20,22-24]. The
leukotriene receptor antagonist montelukast also inhibits
TH2 driven inflammation, and suppresses the LAR
[19,20]. Similarly, it has recently been shown that target-
ing the TH2 cytokines IL-4 and IL-13 by blocking their
common receptor with the IL-4 variant pitrakinra also
inhibits the LAR [21]. PDE4 is expressed on cells
involved in TH2 responses, such as eosinophils and lym-
phocytes [5,27]. The current study would have been
strengthened by proving that GSK256066 had an effect
on these TH2 cells. Nevertheless, our results agree with
previous findings using roflumilast showing that PDE4
inhibition attenuates the LAR [12], suggestive of inhibi-
tion of TH2 inflammation.
There was no change in the secondary endpoint mea-
surements of methacholine challenge post allergen, or
exhaled NO. However, the study was not statistically
powered to examine these secondary endpoints, but was
designed to evaluate the primary endpoint of the allergen
challenge, where unequivocally positive results were
observed. Studies using inhaled corticosteroids have
shown both attenuation [20,24] and no attenuation [22]
of methacholine reactivity post allergen challenge. In line
with these variable results, montelukast has also been
shown to have no effect on methacholine reactivity post
allergen challenge in one study [20] but an inhibitory
effect in another [19]. These variable results suggest that
methacholine reactivity post allergen challenge is not a
robust primary endpoint to evaluate drug effects. It is
clear that GSK256066 inhibits the fall in lung function
during the LAR, but unlike corticosteroids [20,24] we did
not observe inhibition of allergen induced bronchial
hyper-reactivity. This may suggest differentiation of the
effects of PDE4 inhibitors and corticosteroids, although
the inconsistent results in previous studies of methacho-
line reactivity post allergen challenge indicate that cau-
tion should be applied in the interpretation of these data.
Reducing nitric oxide levels by specific iNOS inhibi-
tion does inhibit the EAR or LAR, suggesting that nitric
oxide is not mechanistically involved in the pathophy-
siology of asthma [19]. However, exhaled nitric oxide is
a sensitive biomarker of the effects of inhaled corticos-
teroids [28]. In contrast, the effects of the leukotriene
receptor antagonist singulair are more variable, with no
inhibition observed of nitric oxide observed in some stu-
dies [19,29]. The usefulness of exhaled nitric oxide as a
biomarker appears to vary with the class of drug, and
our results suggest that airway nitric oxide production is
a PDE4 independent mechanism. Alternative explana-
tions are that the current study was too short or under-
powered to detect a reduction in exhaled nitric oxide.
There were few adverse effects in this study, although
larger studies are needed to fully explore the safety pro-
file. However, the lack of nausea and/or gastro-intestinal
side effects usually associated with oral PDE4 inhibitors
[15-17] indicates that the inhaled delivery of a PDE4
inhibitor may minimise the potential for systemic side
effects. The pharmacokinetic analysis performed showed
that systemic exposure to GSK256066 was extremely
low, as some subjects did not have quantifiable exposure
at any time-point despite measurement with a very sen-
sitive analytical assay (LLOQ of 5 pg/mL). Furthermore,
the majority of subjects had levels below the LLOQ
after 4 hrs on days 1 and 7. Additionally, the mean
Cmax of GSK256066 was <20 pg/ml on both of these
days, while measurable levels of the active metabolite
GSK614917 were even lower, underscoring the value of
inhaled delivery to limit systemic exposure and the
potential for systemic side effects. In contrast, the mean
Cmax of roflumilast administered orally is over 2,000
pg/ml with levels of the active metabolite roflumilast N-
Oxide being even higher [30]. Clearly orally adminis-
tered drugs will have higher plasma levels, but this
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exposure with inhaled delivery for GSK256066.
Two subjects were withdrawn from this study with
high creatinine clearance values. This is because the
protocol stated that subjects with abnormal creatinine
clearance values defined by the laboratory reference
range should be withdrawn, in order to exclude patients
who developed renal dysfunction. High creatinine clear-
ance indicates good renal function, so there was no clin-
ical concern about keeping these patients in the study.
However, the wording of the protocol stated that we
had to withdraw these patients as the values were out-
side the laboratory reference range. In retrospect, the
protocol should have stated that patients with low crea-
tinine clearance would be withdrawn.
It has recently been reported that the inhaled PDE4 inhi-
bitor UK-500,001 had no effect on FEV1 after 6 weeks of
treatment in patients with COPD [31]. Oral PDE4 inhibi-
tors have been reported to show clinical efficacy in COPD
patients [15-17], but with a significant rate of side effects.
The effects of PDE4 inhibitors will therefore vary accord-
ing to a variety of factors including the potency of the
drug and the route of delivery. The current study using
inhaled GSK256066 was focused on asthma, and studies
using this drug in COPD would be of interest.
This was the first time that GSK256066 had been
given to patients with asthma, and so the side effect
profile in this population was unknown. PDE4 inhibitors
are known to cause adverse effects [15-17], so we
wanted to limit the duration of exposure in case
GSK256066 caused significant adverse effects. We chose
7 days treatment in order to limit the duration of expo-
sure to a new drug with an unknown side effect profile,
while at the same time treating for long enough to be
able to measure any therapeutic effect. Future studies
can use the preliminary safety data from the current
study to investigate safety and efficacy over a longer
duration, or using other dosing regimens.
In summary, we show that the inhaled PDE4 inhibitor
GSK256066 attenuates the allergen induced changes in
pulmonary function in asthmatics. By limiting systemic
exposure, this therapy has the potential to minimise side
effects usually associated with PDE inhibitors, and war-
rants further study in longer clinical trials.
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